# GPT-5.6 Sol / inf-r02

Original final answer, shared by both scoring rounds.

# Recommended next question

**Do reproducible disagreements between a surface protein and its corresponding transcript represent genuine biological states—particularly transient state transitions or persistent regulation—or are they adequately explained by modality-specific measurement error and cell-mixture effects?**

The highest-value next action is a **calibrated, replicated induction-and-recovery experiment** focused on one or a small number of RNA–surface-protein pairs, with orthogonal measurements on matched aliquots. This should precede development or selection of an “optimal” joint representation because a representation could otherwise turn technical discordance into an apparently coherent state.

Everything below is a **proposed study**, not a report of methods or results from the supplied work. Exact biological system, markers, perturbation, timing, panel, sample size, reagent concentrations, quality thresholds and assay procedures are unreported parameters that must be established prospectively.

---

## 1. Evidence-to-inference-to-conclusion chain

### Supplied evidence

- **E1:** Oligonucleotide-tagged antibodies link selected surface-protein measurements and transcript measurements in the same cells.
- **E2:** The modalities provide complementary information and have different noise and detection properties.
- **E3:** Joint measurement was established, but no optimal integrated representation was specified.
- **E4:** The result did not establish that all apparent RNA–protein disagreements are real cell states, and no later integration benchmark was supplied.

### Inferences

1. Within-cell linkage makes RNA–protein disagreement observable, but does not by itself identify its cause.
2. Because the modalities have different detection properties, an observed RNA-low/protein-high or RNA-high/protein-low cell can arise from technical error in either modality.
3. Genuine biological discordance should be reproducible across independent biological units, validated by measurements not dependent on the same failure mode, and exhibit temporal or state-dependent structure.
4. A joint representation should therefore be evaluated against calibrated biological evidence rather than treated as the definition of a state.

### Conclusion

The central unresolved biological question is whether a given RNA–surface-protein disagreement is:

- a transient stage in a biological transition,
- a persistent regulated state,
- a consequence of broader cell-state composition,
- or a technical observation error.

Resolving that question would determine which disagreements merit mechanistic follow-up and what a useful integrated representation must preserve.

---

## 2. Competing mechanisms and discriminating predictions

The mechanisms are not mutually exclusive; their relative contributions should be estimated.

### Mechanism A: Modality-specific measurement error

Examples include failure to detect an existing transcript, nonspecific antibody-tag signal, weak antibody binding, saturation, background tag counts, variable assay depth or compromised cells.

**Predictions**

- Discordance frequency changes substantially with RNA depth, antibody concentration, background correction, assay batch or quality metrics.
- RNA-low/protein-high events are enriched among cells with generally weak RNA detection; protein-low/RNA-high events are enriched where antibody signal-to-background is poor.
- The apparent states are not consistently reproduced across independently processed biological samples.
- Matched orthogonal RNA or protein measurements do not confirm the relevant difference.
- A calibrated technical-error model accounts for most of the observed joint distribution.
- There is no reproducible directional sequence during induction and recovery.

### Mechanism B: Transient biological lag during a state transition

The transcript and surface protein respond on different timescales. The proposed mechanism may involve delayed protein production or appearance at the surface, or persistence of surface protein after transcript decline; the supplied packet does not establish which molecular step is responsible.

**Predictions**

- After a perturbation that induces the pair, transcript change precedes surface-protein change.
- An RNA-high/protein-low population is enriched early in induction.
- Later, concordant RNA-high/protein-high cells increase.
- After perturbation withdrawal, transcript declines before surface protein, producing RNA-low/protein-high cells.
- The ordering is replicated across biological units and confirmed on matched aliquots.
- Discordant fractions peak near transitions and decline at steady state.
- A model allowing a temporal lag predicts held-out biological samples better than a simultaneous-response or technical-only model.

### Mechanism C: Persistent post-transcriptional or surface-localization regulation

Cells with similar transcript abundance may maintain different surface-protein abundance because of regulation between transcript measurement and surface display.

**Predictions**

- Protein differences remain after conditioning on transcript abundance and technical covariates.
- The discordant groups recur at steady state across independent biological units and batches.
- Protein differences are confirmed by an independent protein readout.
- Discordance is associated with reproducible broader transcript or surface-protein programs rather than isolated count fluctuations.
- Populations prospectively enriched by a live-sortable surface phenotype retain or regenerate the difference under common conditions, subject to imperfect enrichment.
- The pattern persists longer than the transient lag established in the induction/recovery experiment.

A positive result would support regulation downstream of transcript abundance, but would not by itself distinguish protein production, degradation, transport or surface localization.

### Mechanism D: Broader-state composition or omitted-state structure

The pairwise mismatch may mark different cell populations rather than a special regulatory state of that pair.

**Predictions**

- Discordance is concentrated in broader transcript/protein-defined groups.
- Differences between experimental conditions are explained largely by changes in the proportions of those groups.
- Within a sufficiently homogeneous group, the apparent RNA–protein disagreement is reduced or disappears.
- The group is reproducible, but the evidence does not support a direct mechanism linking the specific transcript to its surface protein.

This is biologically meaningful composition, but it is different from demonstrating persistent RNA–protein decoupling within a cell state.

---

# 3. Proposed research plan

## Phase 0: Prerequisites and feasibility

Before a confirmatory experiment, establish the following:

1. **Biological system**
   - Independent biological samples or independently initiated cultures must be available.
   - A single preparation split into many cells is not sufficient biological replication.

2. **Candidate pairs**
   - Each candidate must have a selected surface antibody and measurement of the corresponding transcript.
   - The pair must show usable dynamic range in both modalities.
   - Candidate choice must not be based solely on the most visually striking discordance in the confirmatory data.

3. **Controlled transition**
   - Identify a perturbation and withdrawal or recovery condition expected to change the candidate pair.
   - The exact perturbation, dose and timing are unreported and must be established in a pilot.
   - If no controlled transition is available, the study can distinguish reproducible steady-state discordance from technical noise, but cannot strongly test temporal lag.

4. **Orthogonal validation**
   - A protein measurement not dependent on the same oligonucleotide-tag readout should be available on matched aliquots, preferably with an independently validated binding reagent or readout.
   - An independent RNA measurement should be available on matched aliquots.
   - These need not assay the same individual cells, but must assay aliquots from the same biological unit and condition.

5. **Preservation and handling**
   - Demonstrate that sample handling does not selectively remove one candidate state or materially alter the target measurements.
   - If cryopreservation, transport or prolonged processing is proposed, compare it with the intended reference handling before confirmation.

If antibody specificity, transcript detectability or perturbability cannot be established, stop work on that pair and select another rather than interpreting an uncalibrated mismatch.

---

## Phase 1: Pre-specification

Before examining confirmatory outcomes, register or otherwise lock:

1. The biological question and competing mechanisms.
2. The primary candidate pair or a fixed candidate-selection rule.
3. The independent biological unit.
4. Primary conditions: induction, time-matched control and recovery after withdrawal.
5. Exact confirmatory time points, selected from the pilot.
6. Primary measurements and technical covariates.
7. Quality-control and exclusion rules.
8. The smallest biologically meaningful:
   - directional discordant fraction,
   - transcript-to-protein lag,
   - or protein difference conditional on transcript.
9. The sample-level statistical model and multiplicity correction.
10. Stop rules.
11. Which analyses are confirmatory and which are exploratory.

### Primary estimands

For each candidate pair:

- The biological-sample-level frequency of **RNA-high/protein-low** and **RNA-low/protein-high** cells, adjusted for estimated observation uncertainty.
- The timing of transcript and protein changes relative to perturbation and withdrawal.
- The surface-protein difference between cells with comparable transcript measurements.
- Reproducibility of these quantities across biological units.
- The proportion of apparent discordance attributable to the calibrated technical model.

Hard high/low thresholds should be secondary. The primary analysis should retain continuous measurements and measurement uncertainty.

---

## Phase 2: Assay calibration

Calibration must be completed before the confirmatory study.

### 2.1 Surface-protein calibration

For every candidate antibody:

1. Run an antibody-concentration series on material spanning the expected target range.
2. Include:
   - antibody-omission controls,
   - an irrelevant or nonspecific tagged-antibody control where suitable,
   - independently verified target-low and target-high material if available,
   - process blanks for free-tag or reagent contamination.
3. Select a concentration that provides separation without obvious saturation or excessive background.
4. Test whether background depends on total antibody-tag signal or cell quality.
5. Where feasible, compare with a second binding reagent or independent protein readout.
6. Record reagent identity, lot, concentration, incubation and wash conditions. The supplied packet does not report these.

**Calibration failure:** No target range separates from background, signal is dominated by nonspecific controls, or independent protein measurement contradicts the tagged-antibody signal.

### 2.2 Transcript calibration

1. Measure target-positive and target-low material where independently established.
2. Include process blanks and, if technically compatible, external RNA controls to assess gross processing variability. Such controls do not fully model per-cell capture failure.
3. Determine how the target’s zero or low measurements vary with total RNA information per cell and batch.
4. Use matched aliquots for independent targeted RNA measurement.
5. Evaluate whether additional assay depth continues to recover target signal or has reached a practical plateau.
6. Do not treat every zero count as absence of the transcript.

**Calibration failure:** The target is too sparsely measured to distinguish biological absence from detection failure, or the independent RNA measurement fails to reproduce condition-level differences.

### 2.3 Joint calibration

1. Process matched aliquots of the same biological material independently to estimate technical reproducibility of population frequencies.
2. If feasible, include mixtures of independently verified target-high and target-low populations to evaluate cross-contamination, misclassification and doublets.
3. Assess whether estimated discordant fractions change with:
   - total RNA information,
   - total antibody-tag signal,
   - viability or damage indicators,
   - doublet indicators,
   - processing batch.
4. Establish a reference or bridge sample that can be included across batches, but only if its stability has been demonstrated.

Technical replicates estimate processing variability; they do not replace independent biological replicates.

---

## Phase 3: Pilot temporal study

The pilot determines timing and variance; it is not the definitive mechanistic test.

1. Use several independent biological units, not merely multiple aliquots from one unit.
2. Split each unit, when feasible, across:
   - time-matched untreated or sham control,
   - induction,
   - withdrawal/recovery.
3. Sample densely enough to identify:
   - baseline,
   - initial transcript response,
   - initial protein response,
   - approximate induced steady state,
   - initial transcript decline after withdrawal,
   - protein decline or persistence.
4. At each time, collect:
   - joint single-cell transcript and tagged-surface-protein data,
   - independent RNA data from a matched aliquot,
   - independent protein data from a matched aliquot,
   - viability, cell yield, processing time and batch metadata.
5. Identify the smallest set of confirmatory time points that brackets the inferred ordering.
6. Estimate between-biological-unit variance for power calculations.
7. Lock exact timing and all thresholds before confirmation.

If transcript and protein responses occur outside the sampled window, revise the temporal grid once in the pilot rather than interpreting missing kinetics.

---

## Phase 4: Confirmatory design, allocation and blinding

### 4.1 Independent units and sample size

- The independent unit is the donor, organism, biological specimen or independently initiated culture—whichever is genuinely independent.
- Cells within a unit are subsamples and must not be counted as independent replicates.
- Determine the number of biological units from pilot estimates of between-unit variability and the prespecified minimum meaningful effect.
- No defensible numerical sample size can be derived from the supplied packet.

Where feasible, split each biological unit across all conditions and time points. This paired design separates treatment effects from stable differences among units.

### 4.2 Allocation

1. Randomize aliquots from each biological unit to treatment, control and processing order.
2. Randomize or systematically balance samples across assay batches, operators and lanes/runs.
3. Do not place all controls or all late time points in one batch.
4. Balance candidate target groups and biological units across reagent lots.
5. Maintain an auditable allocation table and deviation log.

### 4.3 Blinding

- Code samples before staining, data generation, quality review and orthogonal measurement.
- The operator applying the perturbation may be impossible to blind, but sample processing and initial quality assessment should remain coded.
- Apply locked quality rules before condition labels are decoded.
- Do not use outcome-aware reruns. Reruns must be triggered by prespecified assay-failure criteria.

---

## Phase 5: Confirmatory experimental sequence

For each biological unit:

1. **Obtain and document the starting material.**
   - Record source, collection time, handling duration and any deviations.

2. **Create paired experimental aliquots.**
   - Allocate to induction, matched control and recovery conditions according to the randomization schedule.

3. **Apply the perturbation.**
   - Use the pilot-selected dose and duration.
   - Use a matched sham or vehicle condition where applicable.

4. **Initiate recovery.**
   - Remove or reverse the perturbation according to the validated pilot procedure.
   - The exact procedure is an unreported parameter.

5. **Collect locked time points.**
   - Process conditions in a balanced order.
   - Record actual rather than intended collection times.

6. **Split each time-point sample.**
   - Aliquot A: joint single-cell transcript and oligonucleotide-tagged surface-protein assay.
   - Aliquot B: independent protein measurement.
   - Aliquot C: independent RNA measurement.
   - Additional aliquot: viability/cell-recovery assessment if not included above.

7. **Run controls with each batch.**
   - Antibody omission.
   - Nonspecific or irrelevant tagged antibody where appropriate.
   - Process blank.
   - Target-high/target-low controls where available.
   - Stable bridge sample if validated.

8. **Record all processing metadata.**
   - Reagent lot, operator, timestamps, order, deviations, cell recovery and assay output.
   - The original packet supplies none of these implementation parameters.

9. **Apply blinded quality control.**
   - Exclude cells or samples only by locked rules.
   - Report the number and reason for every excluded biological unit, aliquot and cell.

---

## Phase 6: Persistence and state-enrichment extension

Run this extension only if the confirmatory study finds reproducible steady-state discordance not explained by the technical model.

1. Identify a live-sortable surface-protein pattern that enriches the proposed discordant groups.
2. Sort or otherwise enrich groups using that pattern.
3. Immediately assay a reserved fraction jointly to quantify actual enrichment; surface phenotype alone cannot prove the transcript state.
4. Place remaining cells from each group into the same environmental condition.
5. Reassay at multiple recovery times using the joint assay and matched orthogonal measurements.
6. Include a mock-sorted control to identify effects of sorting and handling.
7. Repeat across independent biological units.

**Interpretation:** Persistence or regeneration of the difference supports a maintained state. Rapid convergence supports a transient or environmentally imposed state. Because individual cells are destroyed during the joint measurement and enrichment may be imperfect, this is a population-level persistence test, not direct longitudinal tracking of the same cells.

---

# 4. Analysis plan

## 4.1 Quality control without forcing agreement

Do not normalize one modality in a way that assumes it must correlate with the other. Evaluate separately:

- RNA information per cell,
- antibody-tag information per cell,
- background controls,
- cell damage/viability,
- doublet indicators,
- batch and processing time,
- target-specific dynamic range.

All exclusions and transformations must be reported.

## 4.2 Technical observation model

Use calibration data to estimate, separately for RNA and protein:

- background distributions,
- probability of low or absent signal in known positive material,
- between-batch variability,
- dependence on general cell-level quality.

Use this model to predict how many apparent discordant cells would occur if the underlying biological variables were coordinated. This creates a technical null; it does not prove that all residual disagreement is biological.

## 4.3 Mechanism comparison

Fit or otherwise compare prespecified model classes:

1. **Technical-only model:** a coordinated latent biological signal plus calibrated modality errors.
2. **Kinetic model:** protein response can lag transcript response during induction and recovery.
3. **Persistent-state model:** an additional latent state permits different protein abundance at comparable transcript abundance.
4. **Composition model:** broader transcript/protein states explain the apparent pairwise relationship.

Assess performance on held-out biological units, not randomly held-out cells from the same unit. Useful criteria include prediction of:

- directional discordant fractions,
- independent protein measurements,
- independent RNA measurements,
- condition and time-point distributions.

No one model should be declared superior solely because it creates visually cleaner clusters.

## 4.4 Statistical unit and uncertainty

- Estimate effects within each biological unit, then summarize across units with a hierarchical or sample-level analysis.
- Use biological-unit resampling or equivalent sample-level uncertainty calculations.
- Do not generate artificially small uncertainty by treating thousands of cells from one sample as independent.
- Adjust for testing multiple candidate pairs or multiple state definitions.
- Report effect sizes and intervals, not only significance decisions.

## 4.5 Broader-state analysis

Using transcripts and the other selected surface proteins:

1. Define broad states without using the candidate pair as the sole defining feature.
2. Test whether discordance is enriched in those states.
3. Re-estimate the RNA–protein relationship within states.
4. Determine whether treatment changes:
   - the within-state relationship,
   - state proportions,
   - or both.

Discovery of broad states and testing of their reproducibility should use separate biological units or a locked discovery/validation split.

## 4.6 Representation sensitivity

Because the packet supplies no optimal integrated representation, repeat the key conclusions under:

- RNA-only state definitions,
- protein-only state definitions,
- simple scaled concatenation,
- at least one latent joint representation if developed,
- direct target-level analyses without global integration.

A biological conclusion is stronger if it persists across reasonable representations and predicts orthogonal measurements. If it exists only under one representation, it remains representation-dependent and exploratory.

---

# 5. Stop rules

Exact numerical thresholds must be set from the pilot and locked before confirmation.

## Stop a candidate pair if

- Antibody signal cannot be separated from omission/nonspecific controls.
- The protein result is not reproducible on matched aliquots or with an independent protein readout.
- Transcript detection is too sparse to distinguish absence from measurement failure.
- The independent RNA measurement contradicts the direction of the joint-assay result.
- The perturbation does not alter the candidate in either modality.
- Discordance is almost entirely restricted to failed-quality or doublet-like cells.
- Reagent-lot effects are inseparable from biological conditions.

## Stop or repeat a batch if

- Controls fall outside the pre-established calibration range.
- Conditions or time points are confounded with batch.
- Actual collection times depart enough from the locked windows to undermine temporal ordering.
- Cell recovery or viability fails the prespecified criterion.
- A process blank indicates substantial contamination.

## Study-level rules

- Interim review should be limited to blinded quality and safety/feasibility criteria.
- Do not stop early because a desired mechanism appears significant.
- If too few independent biological units remain after prespecified exclusions, report the study as underpowered rather than substituting cell count for replication.
- Any post hoc change creates an exploratory analysis and requires independent confirmation.

---

# 6. Troubleshooting

| Problem | Diagnostic action | Corrective action |
|---|---|---|
| High antibody-tag background | Inspect omission, nonspecific and process controls; test relation to total tag signal | Retitrate reagent, revise washing/handling, change reagent lot or abandon pair |
| Frequent RNA-zero/protein-high cells | Check total RNA information and independent RNA assay | Increase informative sampling or assay performance; model detection uncertainty; do not relabel zeros as true absence |
| Protein-low/RNA-high only in one batch | Examine lot, operator, concentration and batch controls | Repeat a balanced batch; do not interpret the original batch biologically |
| Apparent discordance concentrated in damaged cells | Compare quality metrics and matched viability measurements | Improve handling and apply locked quality exclusions |
| Excess mixed profiles | Examine doublet controls and cell-loading/process parameters | Modify preparation and repeat before mechanistic analysis |
| No temporal separation | Verify perturbation response and increase temporal resolution in the pilot | Revise timing before confirmation; do not infer simultaneity from sparse sampling |
| Independent assays agree at population level but not on state frequency | Check aliquot composition and state instability during processing | Shorten handling, use paired aliquots and interpret only population-level effects |
| Donor-specific result | Examine whether direction is consistent and whether donor characteristics are confounded | Increase independent units; report heterogeneity rather than a universal state |
| One integrated representation creates the state but others do not | Inspect dependence on scaling and modality weighting | Treat the state as representation-dependent until orthogonally validated |

---

# 7. Interpretation of possible outcomes

## Outcome 1: Reproducible temporal lead–lag

**Pattern**

- Transcript changes precede surface-protein changes during induction.
- RNA-high/protein-low cells rise early.
- RNA-low/protein-high cells rise during recovery.
- Matched independent assays confirm the ordering.
- The kinetic model predicts held-out biological units better than the technical-only model.

**Strongest justified conclusion**

For the tested pair, system and conditions, apparent disagreement is at least partly a genuine transitional biological phenomenon consistent with delayed coupling between transcript abundance and surface-protein display.

**Not justified**

- The exact molecular cause of the delay.
- A universal lag for all proteins.
- The claim that every discordant cell is correctly measured.
- A claim that one joint representation is universally optimal.

## Outcome 2: Persistent, orthogonally validated discordance

**Pattern**

- Cells with comparable transcript measurements retain distinct surface-protein levels.
- The difference recurs at steady state across biological units.
- Independent protein measurement confirms it.
- It is associated with a reproducible broader state and persists or regenerates under common conditions.

**Strongest justified conclusion**

The tested system contains a reproducible biological state involving regulation downstream of transcript abundance or differential surface display.

**Not justified**

A specific pathway, direct causality, or distinction among protein production, degradation and localization without additional perturbations.

## Outcome 3: Broader-state or composition explanation

**Pattern**

- Discordance is concentrated in broader cell groups.
- Condition differences are driven mainly by shifts in group proportions.
- Within groups, RNA and protein are substantially more concordant.

**Strongest justified conclusion**

The apparent pairwise disagreement primarily reflects population composition or an omitted broader state. The broader state may be real, but evidence for pair-specific regulatory decoupling is weak.

## Outcome 4: Technical model explains the discrepancy

**Pattern**

- Discordance depends strongly on assay depth, antibody concentration, batch or quality.
- Independent measurements do not confirm it.
- Calibrated observation error reproduces the apparent discordant fractions.
- No ordered temporal pattern is found.

**Strongest justified conclusion**

There is no need to invoke a biological state to explain the observed discrepancy for this pair under these conditions.

This does not prove that biological RNA–protein discordance never occurs.

## Outcome 5: No detectable discordance after calibration

**Strongest justified conclusion**

Within the achieved sensitivity and tested conditions, the modalities do not provide evidence for a distinct discordant state for the candidate pair.

A negative result is limited by the sampled times, perturbation, targets, detection limits and number of biological units.

## Outcome 6: Ambiguous result

Examples:

- Joint assay suggests a state, but only one orthogonal modality confirms it.
- Temporal ordering varies across biological units.
- The target is too sparse in one modality.
- Perturbation response is weak.
- The result depends on a single integration method.
- Stable state and slow kinetics cannot be distinguished within the observation window.

**Conclusion**

No mechanism should be selected. Report the calibrated observations and their uncertainty, identify the limiting failure mode, and repeat only after addressing it.

---

# 8. Main limitations and decision points

1. The packet does not specify the biological system, targets, perturbations or assay parameters, so no exact dose, timing, sample size or acceptance threshold can be justified.
2. Joint measurement is destructive; temporal conclusions compare distributions across cells and times, not repeated measurements of the same cell.
3. Orthogonal measurements on matched aliquots validate populations, not the exact individual cells.
4. Surface-protein measurements do not by themselves distinguish total protein abundance from altered surface localization.
5. A persistent association does not establish a causal molecular pathway.
6. Results for selected surface proteins cannot be generalized to all transcripts or proteins.
7. No integration algorithm should be called optimal without a prespecified benchmark based on replicate prediction and orthogonal biological validation.

**Overall strongest possible conclusion from the proposed study:** for specific RNA–surface-protein pairs and defined conditions, it should be possible to determine whether observed disagreement exceeds calibrated technical error and is best explained by transition kinetics, a persistent regulated state, or broader population composition. The study cannot justify the claim that all observed disagreements are real cell states or identify a universally optimal integrated representation.
